<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Vossen, J.M.J.J.</title>
    <link>http://repub.eur.nl/res/aut/4864/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man (Article)</title>
      <link>http://repub.eur.nl/res/pub/3936/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>We investigated the humoral (antigen-specific immunoglobulin isotypes, IgG subclasses, and avidity maturation) and cellular (antigen-specific in vitro proliferation) immune response in 18 healthy adult volunteers, following a primary and a single booster vaccination with the T-cell dependent neoantigen rabies administered at a 3-months interval. The IgG antibody titer showed a mean 31-fold increase (range 3–154) 4 weeks after the first vaccination and a memory response was observed after booster vaccination, i.e. high IgG titers, switch from IgM to IgG and IgA and increased antibody avidity. All healthy adults showed a rabies-induced proliferative response with a mean stimulation index of 45 (range 3.5–200) after in vitro stimulation of PBMC obtained at 4 weeks after booster vaccination. The results obtained in this study provide a frame of reference for the interpretation of specific immune responses to the T-cell dependent neoantigen rabies in patients suspected of a primary or secondary immunodeficiency. Humoral and cellular immune responses to the rabies neoantigen provide complementary information on the condition of the immune system of an individual. Five patients diagnosed with a combined immunodeficiency were vaccinated using the same protocol and showed a number of abnormalities, either in the humoral or the cellular immune response to the rabies neoantigen.</description>
    </item> <item>
      <title>Radiosensitive SCID patients with Artemis gene mutations show a complete B-cell differentiation arrest at the pre-B-cell receptor checkpoint in bone marrow (Article)</title>
      <link>http://repub.eur.nl/res/pub/8235/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>Severe combined immunodeficiency disease (SCID) can be immunologically
      classified by the absence or presence of T, B, and natural killer (NK)
      cells. About 30% of T(-)B(-)NK(+) SCID patients carry mutations in the
      recombination activating genes (RAG). Some T(-)B(-)NK(+) SCID patients
      without RAG gene mutations are sensitive to ionizing radiation, and
      several of these radiosensitive (RS) SCID patients were recently shown to
      have large deletions or truncation mutations in the Artemis gene, implying
      a role for Artemis in DNA double-strand break (dsb) repair. We identified
      5 RS-SCID patients without RAG gene mutations, 4 of them with Artemis gene
      mutations. One patient had a large genomic deletion, but the other 3
      patients carried simple missense mutations in conserved amino acid
      residues in the SNM1 homology domain of the Artemis protein.
      Extrachromosomal V(D)J recombination assays showed normal and precise
      signal joint formation, but inefficient coding joint formation in
      fibroblasts of these patients, which could be complemented by the
      wild-type Artemis gene. The cells containing the missense mutations in the
      SNM1 homology domain had the same recombination phenotype as the cells
      with the large deletion, indicating that these amino acid residues are
      indispensable for Artemis function. Immunogenotyping and immunophenotyping
      of bone marrow samples of 2 RS-SCID patients showed the absence of
      complete V(H)-J(H) gene rearrangements and consequently a complete B-cell
      differentiation arrest at the pre-B-cell receptor checkpoint-that is, at
      the transition from CyIgmu(-) pre-B-I cells to CyIgmu(+) pre-B-II cells.
      The completeness of this arrest illustrates the importance of Artemis at
      this stage of lymphoid differentiation.</description>
    </item> <item>
      <title>The immunophenotypic and immunogenotypic B-cell differentiation arrest in bone marrow of RAG-deficient SCID patients corresponds to residual recombination activities of mutated RAG proteins (Article)</title>
      <link>http://repub.eur.nl/res/pub/8222/</link>
      <pubDate>2002-01-01T00:00:00Z</pubDate>
      <description>The protein products of the recombination activating genes (RAG1 and RAG2)
      initiate the formation of immunoglobulin (Ig) and T-cell receptors, which
      are essential for B- and T-cell development, respectively. Mutations in
      the RAG genes result in severe combined immunodeficiency disease (SCID),
      generally characterized by the absence of mature B and T lymphocytes, but
      presence of natural killer (NK) cells. Biochemically, mutations in the RAG
      genes result either in nonfunctional proteins or in proteins with partial
      recombination activity. The mutated RAG genes of 9 patients from 7
      families were analyzed for their recombination activity using
      extrachromosomal recombination substrates, rearrangement of endogenous Ig
      loci in RAG gene-transfected nonlymphoid cells, or the presence of Ig gene
      rearrangements in bone marrow (BM). Recombination activity was virtually
      absent in all 6 patients with mutations in the RAG core domains, but
      partial activity was present in the other 3 RAG-deficient patients, 2 of
      them having Omenn syndrome with oligoclonal T lymphocytes. Using 4-color
      flow cytometry, we could define the exact stage at which B-cell
      differentiation was arrested in the BM of 5 RAG-deficient SCID patients.
      In 4 of 5 patients, the absence of recombination activity was associated
      with a complete B-cell differentiation arrest at the transition from
      cytoplasmic (Cy) Igmu(-) pre-B-I cells to CyIgmu(+) pre-B-II cells.
      However, the fifth patient showed low frequencies of precursor B cells
      with CyIgmu and surface membrane IgM, in line with the partial
      recombination activity of the patient's mutated RAG gene and the detection
      of in-frame Ig gene rearrangements in BM.</description>
    </item>
  </channel>
</rss>